Twenty-four-hour blood pressure-lowering effect of a Sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study
Leading orthopedic knee surgeon, Dr
Meta-analysis of gut microbiota alterations in patients with irritable bowel syndrome
Your options include switching to a different GLP-1 medication (tirzepatide acts on multiple hormone pathways, which may work better for some people who don't respond to other medications), asking a specialist to check for underlying metabolic or hormone issues, or trying combination approaches that pair medication with structured behavioral support
Author contributions BL designed the experiments, analyzed the data, and prepared the manuscript
A 46 week gap between treatments is recommended for best results